Market news

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often

Detailed price information for Axogen Inc (AXGN-Q) from The Globe and Mail including charting and trades.

Tipranks Press Release.

Through its BioCircuit buyout, Axogen hopes to extend the market uptake of the former’s NerveTape, a sutureless peripheral nerve repair device.

Axogen Inc. (NASDAQ:AXGN) on Thursday agreed to acquire a privately held medical device manufacturer, BioCircuit Technologies Inc., for $200 million in cash.The strategic acquisition integrates NerveTape, the first FDA-approved sutureless nerve repair device, into Axogen’s existing surgical solutions for restoring peripheral nerve function.Funding The AcquisitionTo finance the $200 million purchase price, Axogen launched an underwritten public offering of 4.91 million shares of common stock, pri

ALACHUA, Fla. and TAMPA, Fla., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (“Axogen” or the “Company”) (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced the pricing of an underwritten public offering of 4,910,000 shares of its common stock at a price to the public of $42.50 per share, before underwriting discounts and commissions. All of the shares to be sold in the proposed offering are

Acquisition adds NerveTape™, the 1st FDA-approved device for sutureless peripheral nerve repair, broadening Axogen’s addressable market within its focus markets Axogen’s commercial infrastructure, surgeon relationships and hospital contracting are expected to accelerate adoption and expand access to NerveTape™ Transaction expected to be accretive to revenue growth, adjusted EBITDA margin and adjusted EPS in the first year following closing while Axogen remains free cash flow positive ALACHUA, Fl

Axogen (AXGN) said Thursday it has priced an underwritten public offering of about 4.9 million share

Axogen (AXGN) has agreed to acquire privately held medical device company BioCircuit Technologies fo

Axogen (AXGN) has an average rating of buy and mean price target of $53.90, according to analysts po

Marc A Began, Executive Vice President & General Counsel, on August 10, 2026, sold 67,500 shares in

Detailed price information for Axogen Inc (AXGN-Q) from The Globe and Mail including charting and trades.

Detailed price information for Incyte Corp (INCY-Q) from The Globe and Mail including charting and trades.

The Axogen investment will be used to progress the technology into Phase II and III clinical studies.

In the second quarter of 2026, Axogen reported sales of US$69.73 million, a net loss of US$1.52 million, and lifted its full-year 2026 revenue outlook to at least US$279 million, implying revenue growth of at least 24%. A key highlight was the rapid expansion of Axogen’s breast reconstruction franchise, which drove more than half of quarterly revenue and reshaped the company’s product mix and margin profile. We’ll now explore how Axogen’s upgraded 2026 revenue outlook and breast...

AxoGen (NASDAQ:AXGN) reported second-quarter 2026 revenue of $69.7 million, up 23.1% from a year earlier, as demand for its Avance nerve graft and broader product portfolio increased across its target markets. The company raised its full-year revenue outlook to at least $279 million, representing gr

Raises Full Year Revenue Guidance to at Least 24% Growth or $279 millionALACHUA, Fla. and TAMPA, Fla., July 29, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today reported financial results and business highlights for the second quarter ended June 30, 2026. Second Quarter Financial Results Revenue was $69.7 million, an increase of 23.1% compared with $56.7 million

Axogen Inc (AXGN) reports a robust 23% revenue increase, driven by the breast market, while navigating margin pressures and strategic expansion.

AxoGen (AXGN) delivered earnings and revenue surprises of +33.33% and +4.31%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Trace Biosciences, Inc., a clinical-stage biotechnology company developing nerve-targeted imaging agents, today announced it has received a strategic investment from Axogen, Inc. (NASDAQ: AXGN), the global leader in surgical solutions for restoration of peripheral nerve function, as its technology continues to advance through clinical development. The investment is part of Trace's Series A financing round with additional investors expected to join.

NZS Capital, LLC, an investment management company, released its “NZS Growth Equity Strategy” second-quarter 2026 investor letter. A copy of the letter can be downloaded here. Equity markets delivered a strong performance in the second quarter of 2026, driven by demand for AI infrastructure, geopolitical stabilization, and positive earnings reports. The portfolio achieved a gross […]

ALACHUA, Fla. and TAMPA, Fla., July 15, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it will release financial results for the second quarter of 2026 on Wednesday, July 29, 2026. Axogen management will host an investment-community conference call and webcast at 8:00 a.m. ET following the release. Investors interested in participating in the con

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.